Sacituzumab govitecan

戈沙妥珠单抗

Report date: 2026/05/08 20:02:52
First In Class

Base Information

Drug NameSacituzumab govitecan
Drug Alias Name戈沙妥组单抗Sacituzumab govitecan-hziyhRS7-SN38 antibody drug conjugateIsactuzumab govitecanTrodelvy +[12] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > CL2A linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > SN-38 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized +[4] 
Mechanisms of ActionAnti-Trop-2DNA topoisomerase I inhibitors
TargetsTumor-associated calcium signal transducer 2DNA topoisomerase I
Therapy Area/IndicationsBrain metastasesMetastatic breast cancerHormone-Resistant Prostate Neoplasms +[36] 
Global Approved IndicationsTriple Negative Breast NeoplasmsBreast Neoplasms
Approved Indications in ChinaTriple Negative Breast Neoplasms
Original Approved Country/TerritoryUnited States
Original Approved Date2020/04/22
Country/TerritoryCzechiaBelgiumBulgaria +[47] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesImmunomedics IncGilead Sciences IncIbc Pharmaceuticals Inc +[4] 
China Registration ClassN/A

Develop Information

Active CompaniesEverest Medicines (Suzhou) IncGilead IncMsd Ireland (Carlow) +[24] 
Inactive CompaniesPfizer IncUniversity Of Washington
Active IndicationsBrain metastasesMetastatic breast cancerSolid tumours +[30] 
Inactive IndicationsHormone-Resistant Prostate NeoplasmsOvarian NeoplasmsPancreatic Neoplasms +[6] 

Other Information

ATC CodeL01XC
Related LinksWikipediaDrugBankKEGG